Anti-CD38 Monoclonal Antibody

Phase 2Small molecule

GGenrix (Shanghai) Biopharmaceutical Co., Ltd.

Anti-CD38 Monoclonal Antibody is one of 56 small molecule programs targeting AL amyloidosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AL AmyloidosisActive, not recruiting

Multiple MyelomaNot yet recruiting

AL AmyloidosisPreclinical

Active, not recruiting

Multiple MyelomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Phase 3

18 2

Venclexta

AbbVie

Phase 3

17 3

Keytruda

Merck & Co.

Phase 3

17 4

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 5

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 6

Opdivo

Bristol-Myers Squibb

Phase 3

11 7

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

23 8

Neulasta

Amgen

Phase 3

5 9

Cytosar

Teva

Phase 3

4 10

Busulfex

Akero Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 1/2Not yet recruiting

Multiple Myeloma

NCT07090954

Clinical

Trials by Indication[1]

AL amyloidosis1 trial

AL Amyloidosis and Anti-CD38-Daratunumab

Completed·UUniversity of Turin, Italy·N/A·NCT06571864·14 enrolled

Multiple Myeloma1 trial

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

Not yet recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 1/2·NCT07090954·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Anti-CD38 Monoclonal Antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-CD38 Monoclonal Antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-CD38 Monoclonal Antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genrix (Shanghai) Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGenrix (Shanghai) Biopharmaceutical Co., Ltd.

Anti-CD38 Monoclonal Antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

AL amyloidosis1 trial

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News